[Skip to Navigation]
August 1972

A New Therapeutic Approach to Candida Infections: A Preliminary Report

Author Affiliations


From the departments of medicine and pediatrics, Harvard Medical School and the Medical and Children's Medical Services, Massachusetts General Hospital and Mount Auburn Hospital (Infectious Disease Units); and the Infectious Disease Service, New England Medical Center, Hospitals and Department of Medicine, Tufts University School of Medicine, Boston. Dr. Medoff is now with the Washington University School of Medicine, St. Louis.

Arch Intern Med. 1972;130(2):241-245. doi:10.1001/archinte.1972.03650020067013

Unusually small intravenous doses of amphotericin B (10 to 355 mg given over 4 to 18 days) were effective in the treatment of 14 selected patients with severe and disabling Candida infections. These included nine with mucocutaneous infections in whom vigorous topical antifungal therapy had failed. Five other patients had systemic disease that had not responded to the removal of intravenous catheters or discontinuation of antibiotics. Follow-up over 2 to 24 months showed no recurrences. No toxicity was encountered except in the recipient of the largest dose, who had transient azotemia. Our limited experience suggests the efficacy of amphotericin B in small nontoxic doses in the treatment of mucocutaneous and systemic Candida infections, excluding meningitis and endocarditis.

Add or change institution